Trevi Therapeutics Inc., a clinical-stage biopharmaceutical company, will participate in the American Cough Conference on June 6 - 7, 2025, in Dulles, Virginia. The company will deliver an oral presentation on June 6 at 4:05 p.m. ET, discussing baseline demographics and characteristics from the RIVER trial evaluating nalbuphine extended-release tablets in patients with refractory chronic cough.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Trevi Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY98124) on May 29, 2025, and is solely responsible for the information contained therein.